High BDNF serum levels are associated to good cognitive functioning in bipolar disorder.


Journal

European psychiatry : the journal of the Association of European Psychiatrists
ISSN: 1778-3585
Titre abrégé: Eur Psychiatry
Pays: England
ID NLM: 9111820

Informations de publication

Date de publication:
08 2019
Historique:
received: 28 12 2018
revised: 18 02 2019
accepted: 18 02 2019
pubmed: 28 2 2019
medline: 4 7 2020
entrez: 28 2 2019
Statut: ppublish

Résumé

Neurotrophins such as brain-derived neurotrophic factor (BDNF), inflammation and oxidative damage may contribute to the pathophysiology of bipolar disorder (BD) in terms of illness activity. To date, there is a lack of studies linking the cognitive impairment observed in BD with these neurobiological mechanisms. This study aimed to investigate the role of these neurobiological factors in clinical and cognitive outcomes in a sample of bipolar individuals. We measured serum BDNF, cytokines and oxidative stress markers in a sample of 133 individuals: 52 euthymic bipolar patients, 32 manic patients and 49 healthy controls. They were all assessed with a comprehensive cognitive battery. Sociodemographic and clinical data were collected. Multiple linear regression models were built to study associations of neurotrophins and inflammatory and oxidative measures with cognitive functioning. BDNF levels were decreased in euthymic (p = 0.039) and manic (p < 0.001) individuals. Conversely, inflammatory (interleukin 6 (IL-6)) (p = 0.019) and oxidative stress (p = 0.003) measures were increased in bipolar individuals compared to controls. BDNF levels were associated with executive functioning (β = 0.01, p = 0.02) and verbal memory (β = 0.013, p = 0.005), together with other demographic variables. In particular, verbal memory was also associated with obesity (β=-0.04, p = 0.005). Neither inflammatory markers, oxidative stress markers nor other relevant clinical variables showed any association with cognitive outcome. Of all the peripheral neurobiological factors analysed, BDNF was the only one significantly associated with cognitive dysfunction in bipolar disorder individuals. This study emphasizes the role of BDNF not only across mood phases but also in cognitive functioning.

Sections du résumé

BACKGROUND
Neurotrophins such as brain-derived neurotrophic factor (BDNF), inflammation and oxidative damage may contribute to the pathophysiology of bipolar disorder (BD) in terms of illness activity. To date, there is a lack of studies linking the cognitive impairment observed in BD with these neurobiological mechanisms. This study aimed to investigate the role of these neurobiological factors in clinical and cognitive outcomes in a sample of bipolar individuals.
METHODS
We measured serum BDNF, cytokines and oxidative stress markers in a sample of 133 individuals: 52 euthymic bipolar patients, 32 manic patients and 49 healthy controls. They were all assessed with a comprehensive cognitive battery. Sociodemographic and clinical data were collected. Multiple linear regression models were built to study associations of neurotrophins and inflammatory and oxidative measures with cognitive functioning.
RESULTS
BDNF levels were decreased in euthymic (p = 0.039) and manic (p < 0.001) individuals. Conversely, inflammatory (interleukin 6 (IL-6)) (p = 0.019) and oxidative stress (p = 0.003) measures were increased in bipolar individuals compared to controls. BDNF levels were associated with executive functioning (β = 0.01, p = 0.02) and verbal memory (β = 0.013, p = 0.005), together with other demographic variables. In particular, verbal memory was also associated with obesity (β=-0.04, p = 0.005). Neither inflammatory markers, oxidative stress markers nor other relevant clinical variables showed any association with cognitive outcome.
CONCLUSIONS
Of all the peripheral neurobiological factors analysed, BDNF was the only one significantly associated with cognitive dysfunction in bipolar disorder individuals. This study emphasizes the role of BDNF not only across mood phases but also in cognitive functioning.

Identifiants

pubmed: 30808582
pii: S0924-9338(19)30044-6
doi: 10.1016/j.eurpsy.2019.02.006
pii:
doi:

Substances chimiques

Biomarkers 0
Brain-Derived Neurotrophic Factor 0
Interleukin-6 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

97-107

Informations de copyright

Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Auteurs

Ester Mora (E)

Psychiatric Service, Hospital Universitari Santa Maria, Biological Foundation of Mental Disorders, Lleida Institute for Biomedical Research Dr. Pifarré Foundation, IRBLleida, University of Lleida, Lleida, Catalonia, Spain; Child and Adolescent Mental Health Centre, Hospital Sant Joan de Déu Terres de Lleida, Catalonia, Spain. Electronic address: ester.mora@sjd-lleida.org.

Maria J Portella (MJ)

Psychiatric Service, Research Institute, Hospital de Santa Creu i Sant Pau, Autonomous University of Barcelona, CIBERSAM, Barcelona, Catalonia, Spain. Electronic address: mportella@santpau.cat.

Gerard Piñol-Ripoll (G)

Cognitive Disorders Unit, Hospital Universitari Santa Maria, Neuroscience Clinical Group, Lleida Institute for Biomedical Research Dr. Pifarré Foundation, IRBLleida, University of Lleida, Lleida, Catalonia, Spain.

Ricard López (R)

Laboratory Department, Hospital Universitari Arnau de Vilanova, Lleida Institute for Biomedical Research Dr. Pifarré Foundation, IRBLleida, University of Lleida, Lleida, Catalonia, Spain.

Daniel Cuadras (D)

Statistics Unit. Sant Joan de Déu Research Fundation, Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Barcelona, Catalonia, Spain.

Irene Forcada (I)

Psychiatric Service, Hospital Universitari Santa Maria, Biological Foundation of Mental Disorders, Lleida Institute for Biomedical Research Dr. Pifarré Foundation, IRBLleida, University of Lleida, Lleida, Catalonia, Spain.

Montse Teres (M)

Psychiatric Service, Hospital Universitari Santa Maria, Biological Foundation of Mental Disorders, Lleida Institute for Biomedical Research Dr. Pifarré Foundation, IRBLleida, University of Lleida, Lleida, Catalonia, Spain.

Eduard Vieta (E)

Bipolar Disorder Program, Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain.

Maria Mur (M)

Psychiatric Service, Hospital Universitari Santa Maria, Biological Foundation of Mental Disorders, Lleida Institute for Biomedical Research Dr. Pifarré Foundation, IRBLleida, University of Lleida, Lleida, Catalonia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH